Goal: The current research project is focused on applying a novel synthetic epigenetic tool (Epi-CRISPRs) for straightforward, one-step pancreatic alpha to beta cell transdifferentiation by targeted DNA methylation and suppression of genes essential for maintaining pancreatic cell identity (homeobox genes Arx and Pax4).
The obtained results will be valuable for later Epi-CRISPRs use in mouse in vivo models of diabetes and eventually as a future therapy for diabetes attenuation in humans.
Period: 2015-2016
